# CGON — Cg Oncology Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CGON  
**Sources:** 16  
**Published:** 2026-10-17  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cgon-cg-oncology-inc-catalysts-narrative-risks-8000

---

## Snapshot (as of the 2026‑10‑16 close)

CG Oncology, Inc. (NASDAQ: CGON) is a late‑stage clinical biopharmaceutical company developing **cretostimogene grenadenorepvec** (CG0070) for non‑muscle‑invasive bladder cancer (NMIBC) in the United States [[1]](https://catalystalert.io/company/CGON)[[5]](https://finance.yahoo.com/healthcare/articles/cg-oncology-appoints-proven-biopharmaceutical-120000549.html)[[17]](https://www.marketbeat.com/stocks/NASDAQ/CGON/). As of 16 October 2026 the stock closed near **$59.85** (down ~3.25% on the day), with a market capitalization of roughly **$5.3 billion** and a 52‑week range of $35.80–$80.97 [[12]](https://tickernerd.com/stock/cgon-forecast/)[[14]](https://stockoscope.com/stock/cgon/news)[[17]](https://www.marketbeat.com/stocks/NASDAQ/CGON/). Note that the unverified background file cited a ~$5.48B market cap and a next‑earnings date of **2026‑11‑09**; the current data providers instead converge on a November 12–13 earnings window and a ~$5.3B cap, so the prior November 9 date should be treated as superseded [[10]](https://tradersunion.com/stocks/earnings/cgon-usd/)[[11]](https://www.marketbeat.com/stocks/NASDAQ/CGON/earnings/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cgon-cg-oncology-inc-catalysts-narrative-risks-8000 (free to sign up)._